Journal Article

Plasma tau-species-positive neuron-derived extracellular vesicles in progressive supranuclear palsy

Get access
Brain, Volume 149, Issue 11, November 2026, Pages 3954–3967, https://doi.org/10.1093/brain/awag091
Published:
06 March 2026
Article history
Received:
08 August 2025
Revision received:
23 January 2026
Accepted:
15 February 2026
Published:
06 March 2026
Corrected and typeset:
22 September 2026

Abstract

The diagnosis of progressive supranuclear palsy (PSP) remains challenging, particularly in differentiating it from Parkinson’s disease (PD) at early stages. Circulating neuron-derived extracellular vesicles (NDEVs), providing a peripheral window into CNS pathology, might serve as promising biomarkers.

A total of 188 participants were recruited from three centres. A discovery cohort [40 PSP patients, 36 PD patients and 31 healthy controls (HCs)] and a multicentre validation cohort (30 PSP patients, 27 PD patients and 24 HCs) were established. NDEVs containing total tau, 4R tau or phosphorylated tau (ptau181, ptau217, ptau231 and ptau396) in plasma samples were analysed using nano-scale flow cytometry. Multivariable logistic regression models were developed in the discovery cohort and strictly validated in the independent cohort using fixed model parameters.

In the discovery cohort, the concentrations of tau-, 4R tau-, ptau181- and ptau217-containing NDEVs in PSP patients were significantly higher than those in HCs and PD patients, whereas ptau396-containing NDEVs showed elevation exclusively in PSP compared with HCs (PSP versus HCs: P < 0.001 for tau, P < 0.001 for 4R tau, P < 0.001 for ptau181, P = 0.008 for ptau217, and P = 0.009 for ptau396; PSP versus PD: P < 0.001 for tau, P < 0.001for4R tau, P = 0.029 for ptau181, and P = 0.003 for ptau217). An integrated model incorporating these biomarkers achieved an area under the curve (AUC) of 0.965 (90.0% sensitivity, 96.8% specificity) for distinguishing PSP from HCs and an AUC of 0.963 (87.5% sensitivity, 94.4% specificity) for distinguishing PSP from PD. In the validation cohort, the concentrations of tau-, 4R tau-, ptau181-, ptau217- and ptau396-containing NDEVs in plasma were significantly higher in PSP patients compared with HCs (PSP versus HCs: P < 0.001 for tau, 4R tau and ptau217, P = 0.03 for ptau181, and P = 0.017 for ptau396). Likewise, the concentrations of tau-, 4R tau-, ptau181- and ptau217- were higher in PSP patients than in PD patients (PSP versus PD: P < 0.001 for tau, 4R tau and ptau217, and P = 0.025 for ptau181). The integrated model yielded an AUC of 0.971 for distinguishing PSP from HCs and 0.990 for distinguishing PSP from PD. Notably, in early-stage patients, the integrated model achieved an AUC of 0.987 in differentiating early-stage PSP from PD.

These findings indicate that plasma tau-species-containing NDEVs are promising biomarkers for PSP, offering high sensitivity and specificity for distinguishing PSP from both HCs and PD, particularly in early disease stages. Further large-scale, longitudinal studies are warranted to validate these findings fully and explore their role in PSP pathophysiology and progression.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights)
You do not currently have access to this article.

Supplementary data

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Please sign in to your personal account to gift article access.

Gift article access

Please create a link below to share with others. This will provide temporary access to this restricted article.

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses.

You have reached the limit of 10 links within a 30 day period